Table 1.
Characteristics of Patients in the Primary and Validation Cohorts after randomization
| Variable | Primary Cohort | Validation Cohort |
|---|---|---|
| Age (years) | 69 (56,81) | 68 ( 55,81) |
| Male, n (%) | 1112 (55.27) | 470 ( 54.71) |
| BMI, n (%) | ||
| Normal | 624 ( 31.01) | 254 (29.57 ) |
| Overweight | 396 ( 19.68) | 203 ( 23.63 ) |
| Obesity | 923 (45.87) | 366 (42.61) |
| Underweight | 69 (3.43 ) | 36 ( 4.19 ) |
| LOS in ICU (days) | 3.7 ( 1.9, 8.9 ) | 2.9 ( 1.9, 9.9 ) |
| SIRS | 3 ( 3, 4) | 3 ( 3, 4) |
| Anemia, n (%) | ||
| Normal | 491 ( 24.40 ) | 176 ( 20.49 ) |
| Mild anemia | 1090 ( 54.17 ) | 460 ( 53.55 ) |
| Moderate anemia | 428 ( 21.27 ) | 222 (25.84 ) |
| Severe anemia | 3 ( 0.15 ) | 1 ( 0.12 ) |
| Glucose ( mmol/L) | 7.0 ( 4.3, 11.9) | 7.0 ( 4.2, 11.4 ) |
| Basline SCr ( umol/L) | 124 ( 80,194) | 124 ( 80,203) |
| Albumin, n (%) | ||
| < 30 g/L | 932 ( 46.32 ) | 420 ( 48.89 ) |
| >= 30 g/L | 1080 ( 53.68 ) | 439 ( 51.11 ) |
| Chronic medical conditions, n (%) | ||
| COPD | 44 ( 2.19 ) | 15 ( 1.75 ) |
| CKD | 338 ( 16.8 ) | 165 ( 19.21 ) |
| Chronic liver disease | 105 ( 5.22 ) | 59 ( 6.87 ) |
| Diabetes | 633 ( 31.46 ) | 254 ( 29.57 ) |
| Coronary disease | 334 ( 16.60 ) | 121 ( 14.09 ) |
| Malignant | 439 ( 21.82 ) | 176 ( 20.49 ) |
| Hypertension | 798 ( 39.66 ) | 311 ( 36.20 ) |
| Comorbidity, n (%) | ||
| Acute pancreatitis | 115 ( 5.72 ) | 39 ( 4.54 ) |
| Lactic acidosis | 469 ( 23.31 ) | 209 ( 24.33 ) |
| Heart failure | 631 ( 31.36 ) | 253 ( 29.45 ) |
| Hypotension | 110 ( 5.47 ) | 54 ( 6.29 ) |
| Medication, n (%) | ||
| Vasoactive drugs | 891 ( 44.28 ) | 388 ( 45.17 ) |
| Diuretic | 760 ( 37.77 ) | 301 ( 35.04 ) |
| Aminoglycosides | 1516 ( 75.35 ) | 645 ( 75.09 ) |
| Lactated Ring | 118 ( 5.86 ) | 52 ( 6.05 ) |
| Human albumin | 222 ( 11.03 ) | 91 ( 10.59 ) |
BMI body mass index; SCr Serum creatinine; LOS in ICU length of stay in intensive care unit; SIRS Systemic inflammatory score; COPD chronic obstructive pulmonary disease; CKD chronic kidney disease